Skip to content

Hormonal

All peptides
Posterior-pituitary neuropeptide

Oxytocin

Also known as: Pitocin, Syntocinon, OT

The labor-induction hormone (Pitocin), FDA-approved since 1962. Off-label nasal and subcutaneous use — for autism social cognition, 'bonding,' anxiolysis — has loud community framing but a messier and partly negative randomized-trial literature.

Reviewed 2026-05-04

What it does

Oxytocin is a 9-amino-acid hormone produced in the hypothalamus and released from the posterior pituitary. The IV form (Pitocin / Syntocinon) has been FDA-approved since 1962 for labor induction and postpartum hemorrhage management — that's the bedrock medical indication. The story that drives community interest, however, is the off-label use of intranasal or subcutaneous oxytocin for social cognition (autism), pair-bonding, anxiety, and trust — uses that ride on a captivating mechanistic story but a much messier randomized-trial literature, with several large negative trials in autism and ongoing debate about whether intranasal delivery actually reaches central oxytocin receptors at clinically meaningful concentrations.

Used for

Dose

Starting
1 mcg · continuous IV titration
Common
21 mcg · continuous IV titration
Upper
40 mcg · continuous IV titration
When
Before activityBonding / social-context use; dose 30–60 min before the relevant interaction. No daily-rhythm chronopharmacology — placeholder time targets a typical late-afternoon / evening social window.
Site
intravenous (labor induction, approved indication)

Need exact volumes? Open the peptide calculator →

⚠ Caution

  • Significant cephalopelvic disproportion or unfavorable fetal position (IV labor use)
  • Hypertensive disorders without obstetric supervision
  • Hypersensitivity to oxytocin or formulation excipients
  • History of hyponatremia (high-dose IV oxytocin can cause water intoxication)
  • Cardiac disease — IV oxytocin can cause hypotension and reflex tachycardia
  • Off-label nasal/SubQ use in pregnancy is contraindicated unless under obstetric supervision (uterine activity risk)
  • Caution with concurrent vasoconstrictors (additive hypertensive effect)

Your stack

Track this peptide in your protocol — dose, schedule, vials on hand, refill projection. Stays in your browser; no account needed.

Add to my stack

Use this peptide

Reconstitution & storage

FDA-approved IV product is supplied pre-mixed; not patient-reconstituted. Compounded intranasal oxytocin is typically supplied as a sterile aqueous solution at concentrations like 40 IU/mL (≈68 mcg/mL); a typical 50 µL nasal spray actuation delivers ≈2 IU. Compounded SubQ oxytocin should be verified per batch — concentrations vary widely.

Storage. FDA-approved IV: refrigerate per label. Compounded intranasal: refrigerate 2–8 °C, use within label expiration (commonly 30 days for compounded preparations). Intact peptide is sensitive to heat and pH.

Open the peptide calculator →

Monitoring & questions

Reported side effects
  • IV: uterine hyperstimulation, fetal distress, hyponatremia (water intoxication at sustained high doses), hypotension on rapid bolus
  • Intranasal: nasal irritation, headache, occasional emotional reactivity (some autism trials reported behavioral changes including increased irritability)
  • SubQ: injection-site reactions
  • Theoretical / reported in chronic off-label use: emotional blunting after extended use, altered social-reward processing, paradoxical anxiety in some users
  • Rare: anaphylactoid reactions
Biomarkers Juno tracks

Reference

How it works

Agonist at the oxytocin receptor (OXTR), a Gq-coupled GPCR. Peripheral effects: uterine smooth-muscle contraction, milk-ejection reflex. Central effects: modulation of social cognition, fear extinction, pair-bonding behaviors via OXTR expression in the amygdala, nucleus accumbens, and hypothalamus. The crux of the off-label literature is whether intranasal delivery achieves meaningful CNS concentrations — direct CSF measurements after intranasal administration in humans show inconsistent and modest increases.

Juno's take

Oxytocin earns the per-indication framing more than almost any other entry here. The decades-old labor-induction use is bedrock medicine. The autism social-cognition story has a more complicated arc — several promising small trials, then a large rigorous randomized trial that didn't replicate the benefit. The 'love hormone' framing for general pair-bonding is genuinely contested, with persistent unresolved questions about whether intranasal delivery even reaches the brain at meaningful doses.

EvidenceTier 1 — Human RCT

Tiers are per indication. The same molecule can be Tier 1 for one use and Tier 4 for another — the tier reflects published literature, not community framing.

Labor induction and augmentation (FDA-approved)

Tier 1high confidence

FDA approved as Pitocin since 1962. Standard of care globally. Decades of obstetric trial and registry data support efficacy and characterize the safety profile (uterine hyperstimulation, hyponatremia at high doses).

American College of Obstetricians and Gynecologists et al. 2009

Postpartum hemorrhage prevention/treatment (FDA-approved)

Tier 1high confidence

Active management of the third stage of labor with oxytocin reduces postpartum hemorrhage risk; recommended by WHO and ACOG.

American College of Obstetricians and Gynecologists et al. 2009

Social cognition / autism spectrum disorder (intranasal)

Tier 2high confidence

Many small early RCTs of intranasal oxytocin in autism showed positive effects on social cognition. Larger, more rigorous trials — including the SOARS-B Phase 2 RCT (Sikich et al., NEJM 2021, n=290 children) — found NO significant improvement on the primary social-behavior endpoint over 24 weeks. Tier 2 with a strong note on the negative replication (Rule 8: when evidence conflicts, tier conservatively).

Sikich L et al. 2021

Anxiety / fear extinction / PTSD (off-label intranasal)

Tier 3medium confidence

Mechanistically supported by amygdala OXTR studies. Small human trials are mixed; no replicated large RCT establishing efficacy as a stand-alone or adjunct therapy. Some signal in PTSD-prevention paradigms; not established.

MacDonald E et al. 2011

Pair-bonding / 'love hormone' / relationship enhancement

Tier 3high confidence

Animal studies (prairie voles, etc.) and small human trials drive the popular narrative. Replication has been uneven, several effects have failed to replicate, and intranasal CNS bioavailability questions are unresolved. Treat consumer-facing 'connection in a bottle' framing skeptically.

MacDonald E et al. 2011

Subcutaneous off-label use (anxiolysis, libido, general wellness)

Tier 3high confidence

Compounding-pharmacy and wellness-clinic SubQ oxytocin is a substantial market with no published RCT support for these indications via the SubQ route specifically. Doses typical for SubQ are far below the IV labor doses; bioavailability and CNS penetration via SubQ are not characterized.

No primary citations are anchored to this indication — the tier reflects the absence of usable literature, not a missing reference.

Citations (3)
  1. [1]
    ACOG Practice Bulletin No. 107: Induction of labor
    American College of Obstetricians and Gynecologists · Obstetrics & Gynecology · 2009 · PMID 19623003
    Tier 1 anchor for the FDA-approved labor-induction indication; reflects standard-of-care guidance.
    View source
  2. [2]
    Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder
    Sikich L, Kolevzon A, King BH, et al. · New England Journal of Medicine · 2021 · PMID 34644471
    Largest rigorous RCT of intranasal oxytocin in ASD; primary endpoint negative. Defines the editorial framing for the autism indication.
    View source
  3. [3]
    A Review of Safety, Side-Effects and Subjective Reactions to Intranasal Oxytocin in Human Research
    MacDonald E, Dadds MR, Brennan JL, Williams K, Levy F, Cauchi AJ. · Psychoneuroendocrinology · 2011 · PMID 21484082
    Cross-indication safety and subjective-effect review supporting Tier 3 framing for anxiety / bonding / off-label nasal use.
    View source